News
12-09-2010, 08:17 AM
Boehringer Ingelheim Pharmaceuticals, Inc. announced the initiation of a phase III clinical trial in the United States to investigate one of its oncology pipeline compounds, afatinib* (BIBW 2992), for the treatment of patients with advanced (metastatic) breast cancer...
More... (http://mnt.to/f/3NNV)
More... (http://mnt.to/f/3NNV)